Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle
A protein hub identified in blood cancer shows potential when combined with checkpoint inhibitors and other drugs, pending clinical testing.
LASSO-based immune prognostic modeling in 751 MM patients identified MCM2 as a key hub gene; preclinical data show MCM2 inhibition enhances PD1/PDL1 checkpoint blockade efficacy. Combined MCM2 + CDK inhibitor + immunotherapy represents a novel triple-modality strategy pending clinical validation.
What the study was
- Study design
- Bioinformatics + in vitro/in vivo validation
- Population
- MM patients (RNA-seq n=751) + in vitro/in vivo validation
- Sample size
- 751
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cellular Oncology
Why it surfaced
Large bioinformatics n=751 + in vitro/vivo validation; novel MCM2 therapeutic target in MM with immunotherapy synergy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.